All sponsors

Candel Therapeutics, Inc. $CADL

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS1
Open Candel Therapeutics, Inc. on the live radar map → 📅 $CADL readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
PrTK03
NCT01436968
P3Active, not recruitingProstate Cancer7112024-08 (+107 mo)
aglatimagene besadenovec
NCT02768363
P2Active, not recruitingProstate Cancer1872024-11 (+83 mo)
Aglatimagene besadenovec
NCT04495153
P2Active, not recruitingNon Small Cell Lung Cancer902024-12-31 (+31 mo)
aglatimagene besadenovec + valacyclovir
NCT07332000
P2RecruitingProstate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma)452027-02
LuTK03
NCT07660094
P3RecruitingNon-squamous, Non-Small Cell Lung Cancer5002031-10-22